177 related articles for article (PubMed ID: 21345188)
1. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data.
Mapel DW; Dutro MP; Marton JP; Woodruff K; Make B
BMC Health Serv Res; 2011 Feb; 11():43. PubMed ID: 21345188
[TBL] [Abstract][Full Text] [Related]
2. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients.
Make B; Dutro MP; Paulose-Ram R; Marton JP; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2012; 7():1-9. PubMed ID: 22315517
[TBL] [Abstract][Full Text] [Related]
3. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Predictive Model to Identify Individuals Likely to Have Undiagnosed Chronic Obstructive Pulmonary Disease Using an Administrative Claims Database.
Moretz C; Zhou Y; Dhamane AD; Burslem K; Saverno K; Jain G; Devercelli G; Kaila S; Ellis JJ; Hernandez G; Renda A
J Manag Care Spec Pharm; 2015 Dec; 21(12):1149-59. PubMed ID: 26679964
[TBL] [Abstract][Full Text] [Related]
5. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
6. The Identification and Cost of Acute Chronic Obstructive Pulmonary Disease Exacerbations in a United States Population Healthcare Claims Database.
Stanford RH; Engel-Nitz NM; Bancroft T; Essoi B
COPD; 2020 Oct; 17(5):499-508. PubMed ID: 32962447
[TBL] [Abstract][Full Text] [Related]
7. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
[TBL] [Abstract][Full Text] [Related]
8. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
9. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
Trantham L; Sikirica MV; Candrilli SD; Benson VS; Mohan D; Neil D; Joshi AV
J Med Econ; 2019 Apr; 22(4):319-327. PubMed ID: 30580639
[TBL] [Abstract][Full Text] [Related]
10. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
11. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
Schwab P; Dhamane AD; Hopson SD; Moretz C; Annavarapu S; Burslem K; Renda A; Kaila S
Int J Chron Obstruct Pulmon Dis; 2017; 12():735-744. PubMed ID: 28260880
[TBL] [Abstract][Full Text] [Related]
12. External Validation of a COPD Risk Measure in a Commercial and Medicare Population: The COPD Treatment Ratio.
Stanford RH; Lau MS; Li Y; Stemkowski S
J Manag Care Spec Pharm; 2019 Jan; 25(1):58-69. PubMed ID: 30589629
[TBL] [Abstract][Full Text] [Related]
13. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.
Abudagga A; Sun SX; Tan H; Solem CT
Int J Chron Obstruct Pulmon Dis; 2013; 8():175-85. PubMed ID: 23589684
[TBL] [Abstract][Full Text] [Related]
14. A 4-Year Retrospective Claims Analysis of Oral Corticosteroid Use and Health Conditions in Newly Diagnosed Medicare FFS Patients with COPD.
Bazell C; Pollack M; Comellas AP; Sethi S; Alston M; Pyenson B; Hansen D; Caplen M; Staresinic A; Styczynski J; Feigler N
Int J Chron Obstruct Pulmon Dis; 2022; 17():2635-2652. PubMed ID: 36274995
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
[TBL] [Abstract][Full Text] [Related]
16. Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population.
AbuDagga A; Sun SX; Tan H; Solem CT
J Med Econ; 2013; 16(3):421-9. PubMed ID: 23336296
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting.
Stephenson JJ; Wertz D; Gu T; Patel J; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2017; 12():1947-1959. PubMed ID: 28740375
[TBL] [Abstract][Full Text] [Related]
18. Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.
Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Vekeman F; Gauthier-Loiselle M; Duh MS; Merrigan JF; Schatz M
Ann Am Thorac Soc; 2016 Jul; 13(7):1067-75. PubMed ID: 27070274
[TBL] [Abstract][Full Text] [Related]
19. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
Singer D; Bengtson LGS; Elliott C; Buikema AR; Franchino-Elder J
Int J Chron Obstruct Pulmon Dis; 2020; 15():3239-3250. PubMed ID: 33324047
[TBL] [Abstract][Full Text] [Related]
20. Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population.
Simoni-Wastila L; Yang HW; Blanchette CM; Zhao L; Qian J; Dalal AA
Curr Med Res Opin; 2009 Nov; 25(11):2729-35. PubMed ID: 19778165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
